Targeting CMTM6: A Protein with Potential as A Drug Target Or Biomarker

Target Name: CMTM6

NCBI ID: G54918

CMTM6

Targeting CMTM6: A Protein with Potential as A Drug Target Or Biomarker

CMTM6 (Pro2219) is a protein that is expressed in various tissues of the body, including the brain, heart, kidneys, and liver. It is a member of the CMTM (Cytoskeleton-associated protein tyrosine modifier) family, which is known for their role in modifying the cytoskeleton of cells.

One of the unique features of CMTM6 is its ability to interact with several different proteins, including the protein p185. This interaction between CMTM6 and p185 has been shown to play a role in the regulation of cellular processes such as cell adhesion, migration, and invasion.

Another interesting feature of CMTM6 is its ability to modulate the activity of the protein kinase ALCI (alpha-latency interval kinase). This protein is known for its role in the regulation of cell cycle progression and has been shown to play a role in the development of cancer.

CMTM6 has also been shown to interact with the protein Fyn, which is known for its role in the regulation of cell signaling pathways. This interaction between CMTM6 and Fyn has been shown to play a role in the regulation of cellular processes such as cell adhesion and migration.

In addition to its interactions with other proteins, CMTM6 has also been shown to play a role in the regulation of cellular processes such as cell growth, apoptosis, and autophagy.

Given its unique combination of features, CMTM6 has potential as a drug target or biomarker. Studies have shown that inhibiting the activity of CMTM6 has been shown to have therapeutic effects in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One potential approach to targeting CMTM6 is to use small molecules or antibodies that specifically interact with its unique features. For example, inhibitors of CMTM6 that have been shown to have therapeutic effects in animal models of cancer have been shown to have potential as a new treatment option for cancer.

Another potential approach to targeting CMTM6 is to use drugs that specifically modulate its activity. For example, drugs that inhibit the activity of CMTM6 and increase its levels have been shown to have therapeutic effects in animal models of neurodegenerative diseases.

Overall, CMTM6 is a protein that has significant potential as a drug target or biomarker. Its unique combination of features and its ability to interact with multiple proteins make it an attractive target for the development of new therapies for a variety of diseases.

Protein Name: CKLF Like MARVEL Transmembrane Domain Containing 6

Functions: Master regulator of recycling and plasma membrane expression of PD-L1/CD274, an immune inhibitory ligand critical for immune tolerance to self and antitumor immunity. Associates with both constitutive and IFNG-induced PD-L1/CD274 at recycling endosomes, where it protects PD-L1/CD274 from being targeted for lysosomal degradation, likely by preventing its STUB1-mediated ubiquitination. May stabilize PD-L1/CD274 expression on antigen presenting cells and potentiates inhibitory signaling by PDCD1/CD279, its receptor on T-cells, ultimately triggering T-cell anergy

The "CMTM6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CMTM6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets